Author

Emily A. Nizialek

AstraZeneca (United Kingdom)ORCID 0000-0001-5447-7371Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:differential expression· 1 Organism:human· 1 Approach:statistical model· 1 Assay:whole-exome sequencing· 1

Frequent Co-Authors

Anton Mikhailovich SafonoviD· 1 shared Antonio MarraiD· 1 shared Ben O’LearyiD· 1 shared Bob T. LiiD· 1 shared Bradley Stephen WubbenhorstiD· 1 shared Chaitanya BandlamudiiD· 1 shared Dara S. RossiD· 1 shared David B. SolitiD· 1 shared

Activity by Year

2024-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperGenomics

Anton Mikhailovich SafonovORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

GenomicsbioRxivPreprintFeb 5, 2024

Tumor suppressor heterozygosity and homologous recombination deficiency mediate resistance to front-line therapy in breast cancer

Anton Mikhailovich Safonov, Antonio Marra, Chaitanya Bandlamudi…·Pedram Razavi

The paper identifies how germline and somatic mutations interact to cause resistance to CDK4/6 inhibitors in breast cancer and proposes a sequential treatment strategy using PARP inhibitors.

18 citations

humanwhole-exome sequencing

𝕏 PostBluesky